TNFRSF17 and Miyoshi myopathy: Autologous SLAMF-7 targeting CAR-Ts (NCT04499339, NCT03958656, NCT03710421), allogeneic SLAMF-7 targeting CAR-Ts (NCT04142619), and BCMA/SLAMF-7 targeting CAR-Ts (NCT04662099, NCT04156269) have been engineered for R/R MM patients [54, 71, 84, 93].